What question did this study set out to answer?

This research aims to synthesize evidence on how stress affects the benefits and risks of central stimulants in ADHD treatment.

February 26, 2026Neuropsychiatric Disease and Treatment0 citationsOpen Access

Central Stimulants in a Stressed Brain: Evidence Synthesis of Benefits, Burnout Risk, and Clinical Safeguards in ADHD

Q: What does this research mean for the field?

Central stimulants improve core ADHD symptoms but their effectiveness is reduced under sustained psychosocial or financial stress. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.NEUTRAL.

DADavoud Amiri LBLamberto Briziarelli SSSwetang J Shah

Key Points

This research aims to synthesize evidence on how stress affects the benefits and risks of central stimulants in ADHD treatment.
Conducted a narrative synthesis based on systematic searches of MEDLINE/PubMed, Embase, and PsycINFO from 2010 to 2025.
Implemented dual screening and data extraction for included studies, assessing risk of bias and certainty of evidence.
Examined primary studies relating to stress-linked vulnerability and functional outcomes in ADHD.
Stimulants improved inattention and working memory but had mixed outcomes for emotion regulation under stress.
Functional benefits were weaker in individuals with higher psychosocial stress or financial strain, with increased irritability and sleep disturbances.
Moderation effects were suggested by drug class, dose, and timing, but specific comparative evidence was limited.

Abstract

Background: Central stimulants improve core ADHD symptoms, yet day-to-day benefit and tolerability vary under sustained psychosocial or financial stress. We reviewed clinical outcomes relevant to stress-linked vulnerability and integrated mechanistic evidence on stress-sensitive prefrontal–nucleus accumbens dopamine–glutamate pathways. Methods: Narrative evidence synthesis with systematic searches of MEDLINE/PubMed, Embase and PsycINFO (2010–March 2025). Dual screening and data extraction; risk of bias (RoB 2/ROBINS-I) and GRADE certainty by outcome domain. Meta-analysis was prespecified but not executed because no domain met pooling criteria; findings are presented narratively by outcome domain and stress context. Results: Fifteen primary studies met inclusion (8 RCTs; 7 cohorts). Stimulants consistently improved inattention/working memory and daytime task efficiency. Evidence for emotion- and stress-linked outcomes (emotion dysregulation, irritability, sleep disturbance/fatigue, anxiety/depression, real-world functioning) was mixed and context-dependent. In samples exposed to higher psychosocial stress or financial strain, functional benefits appeared attenuated and irritability, sleep disturbance and fatigue relatively more frequent. Signals suggested moderation by drug class, dose and timing (notably late-day “booster” dosing), but direct comparative evidence was limited. Overall certainty was moderate for core symptoms and low-to-moderate for stress-linked outcomes. Conclusion: Stimulants remain effective for core ADHD symptoms, but sustained stress may narrow the therapeutic window. Clinical safeguards include dose timing (avoid routine evening/booster dosing), sleep protection, load management, and proactive treatment of comorbidity. Stress-stratified trials with standardised outcomes are needed. Registration: Not preregistered; protocol prespecified. Keywords: ADHD, stimulants, stress, emotion dysregulation, sleep, dose timing, financial strain

AI से पूछें

Bookmark

View Full Paper